title: Effects of decoy molecules targeting NF-kappaB transcription factors in Cystic fibrosis IB3-1 cells: recruitment of NF-kappaB to the IL-8 gene promoter and transcription of the IL-8 gene.
abstract: One of the clinical features of cystic fibrosis (CF) is a deep inflammatory process, which is characterized by production and release of cytokines and chemokines, among which interleukin 8 (IL-8) represents one of the most important. Accordingly, there is a growing interest in developing therapies against CF to reduce the excessive inflammatory response in the airways of CF patients. Since transcription factor NF-kappaB plays a critical role in IL-8 expression, the transcription factor decoy (TFD) strategy might be of interest. In order to demonstrate that TFD against NF-kappaB interferes with the NF-kappaB pathway we proved, by chromatin immunoprecipitation (ChIP) that treatment with TFD oligodeoxyribonucleotides of cystic fibrosis IB3-1 cells infected with Pseudomonas aeruginosa leads to a decrease occupancy of the Il-8 gene promoter by NF-kappaB factors. In order to develop more stable therapeutic molecules, peptide nucleic acids (PNAs) based agents were considered. In this respect PNA-DNA-PNA (PDP) chimeras are molecules of great interest from several points of view: (1) they can be complexed with liposomes and microspheres; (2) they are resistant to DNases, serum and cytoplasmic extracts; (3) they are potent decoy molecules. By using electrophoretic mobility shift assay and RT-PCR analysis we have demonstrated that (1) the effects of PDP/PDP NF-kappaB decoy chimera on accumulation of pro-inflammatory mRNAs in P.aeruginosa infected IB3-1 cells reproduce that of decoy oligonucleotides; in particular (2) the PDP/PDP chimera is a strong inhibitor of IL-8 gene expression; (3) the effect of PDP/PDP chimeras, unlike those of ODN-based decoys, are observed even in the absence of protection with lipofectamine. These informations are of great impact, in our opinion, for the development of stable molecules to be used in non-viral gene therapy of cystic fibrosis.
authors: ER-GenTech and BioPharmaNet, Department of Biochemistry and Molecular Biology, Università di Ferrara, Ferrara, Italy.
authors: Alessia
authors: A
authors: Finotti
authors: Monica
authors: M
authors: Borgatti
authors: Valentino
authors: V
authors: Bezzerri
authors: Elena
authors: E
authors: Nicolis
authors: Ilaria
authors: I
authors: Lampronti
authors: Maria
authors: M
authors: Dechecchi
authors: Irene
authors: I
authors: Mancini
authors: Giulio
authors: G
authors: Cabrini
authors: Michele
authors: M
authors: Saviano
authors: Concetta
authors: C
authors: Avitabile
authors: Alessandra
authors: A
authors: Romanelli
authors: Roberto
authors: R
authors: Gambari
mesh_terms: D001483:Base Sequence; D002460:Cell Line; D003550:Cystic Fibrosis / Q000382:microbiology / Q000473:pathology*; D004247:DNA / Q000378:metabolism; D006801:Humans; D016209:Interleukin-8 / Q000235:genetics*; D016328:NF-kappa B / Q000378:metabolism*; D009838:Oligodeoxyribonucleotides / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D020135:Peptide Nucleic Acids / Q000378:metabolism; D011401:Promoter Regions, Genetic / Q000187:drug effects* / Q000235:genetics*; D011550:Pseudomonas aeruginosa / Q000502:physiology; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D016209:Interleukin-8; D016328:NF-kappa B; C468119:NF-kappaB decoy; D009838:Oligodeoxyribonucleotides; D020135:Peptide Nucleic Acids; D004247:DNA